In addition to CG001419, Cullgen continues the advancement of CG009301, a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, as well as progressing its pipeline of pre ...
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutationPhase 2 results ...
Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive results from the Phase 2 SUMIT-BC clinical ...
Hormonal fluctuations throughout a woman's life are among the factors that most influence the immune system. Like a seesaw, ...
SDLC guides teams to plan, build, test, and deliver software. Discover phases, KPIs, tools, and checklist with our quick start guide. Picture this: You and your team have spent a tremendous amount of ...
The cell cycle is a fundamental process vital for organismal growth and stability. Its dysregulation underlies many human diseases, in particular cancers, making its monitoring essential in biological ...
A new research paper was published in Volume 17, Issue 8 of Aging-US on August 7, 2025, titled "Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status ...
Figure 6. Senescent heterogeneity model based on DNA content. Compared to G1-arrested cells, G2-arrested senescent cells express higher levels of senescence-associated markers, secrete more IL-6, and ...
Trial results could underpin request for regulatory approval Bayer already working on manufacturing network Several other research teams working on similar treatments SAN SEBASTIAN, Spain, Sept 22 ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Between Aug 31, 2022, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback